NCT00607438 - A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Breast Cancer

Interventions

DRUG

Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)

125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.

DRUG

Sorafenib (Nexavar)

400 mg orally twice a day continuously (even during rest week) starting on Day 1.

Trial Locations (1)

Veeda Oncology, Columbus